Compare UVE & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | UVE | EVO |
|---|---|---|
| Founded | 1990 | 1993 |
| Country | United States | Germany |
| Employees | N/A | 4766 |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 925.9M | 821.2M |
| IPO Year | 1996 | N/A |
| Metric | UVE | EVO |
|---|---|---|
| Price | $34.86 | $2.35 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $40.00 | $7.00 |
| AVG Volume (30 Days) | ★ 199.0K | 110.0K |
| Earning Date | 04-23-2026 | 05-05-2026 |
| Dividend Yield | ★ 2.32% | N/A |
| EPS Growth | ★ 214.43 | N/A |
| EPS | ★ 6.32 | N/A |
| Revenue | ★ $1,603,915,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.88 | $7.13 |
| P/E Ratio | $5.24 | ★ N/A |
| Revenue Growth | ★ 5.48 | N/A |
| 52 Week Low | $20.83 | $2.31 |
| 52 Week High | $36.68 | $4.80 |
| Indicator | UVE | EVO |
|---|---|---|
| Relative Strength Index (RSI) | 58.11 | 27.69 |
| Support Level | $30.42 | $2.31 |
| Resistance Level | $35.62 | $3.78 |
| Average True Range (ATR) | 0.94 | 0.08 |
| MACD | -0.16 | -0.02 |
| Stochastic Oscillator | 59.19 | 6.03 |
Universal Insurance Holdings Inc is a private personal residential homeowner insurance company. The company develops, markets, and underwrites insurance products for consumers predominantly in the personal residential homeowners' lines of business and performs substantially all other insurance-related services for its primary insurance entities, including risk management, claims management, and distribution. The company generates revenue from the collection of premiums, earned net interest and dividend income from the investment portfolio, the collection of reinsurance recoverable and financing fees. The company's primary insurance subsidiaries, (UPCIC) and (APPCIC) provide insurance for personal residential: homeowners, renters/tenants, condo unit owners, and other related coverages.
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.